Eastwood Bio-Medical Canada Inc.
EWOOF · OTC
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 10.00 | -0.95 | 4.33 | -3.37 |
| FCF Yield | -0.03% | 0.02% | -0.00% | 0.00% |
| EV / EBITDA | -885.30 | -614.14 | -1,715.53 | -834.10 |
| Quality | ||||
| ROIC | 9.41% | 13.63% | 7.60% | 19.43% |
| Gross Margin | 69.54% | 63.94% | 69.76% | 38.32% |
| Cash Conversion Ratio | 0.15 | -0.09 | 0.02 | -0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.39% | -9.02% | -8.69% | -2.59% |
| Free Cash Flow Growth | -253.28% | 1,029.50% | -147.01% | 192.82% |
| Safety | ||||
| Net Debt / EBITDA | -0.70 | -0.32 | -1.22 | -0.32 |
| Interest Coverage | 0.00 | 0.00 | 102.89 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | -5.88 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -170.69 | -220.81 | -118.41 | -57.27 |